Broadfin Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-7,258,135
Closed -$37.5M 53
2019
Q2
$37.5M Hold
7,258,135
8.15% 2
2019
Q1
$26.1M Buy
7,258,135
+3,175,000
+78% +$13.8M 5.4% 4
2018
Q4
$25M Hold
4,083,135
3.29% 6
2018
Q3
$23.8M Sell
4,083,135
-211,291
-5% -$1.06M 3.51% 9
2018
Q2
$18.3M Hold
4,294,426
2.87% 12
2018
Q1
$18.9M Hold
4,294,426
2.95% 13
2017
Q4
$22.6M Sell
4,294,426
-890,516
-17% -$5.45M 3.69% 11
2017
Q3
$31.8M Hold
5,184,942
4.7% 7
2017
Q2
$37.5M Buy
5,184,942
+1,489,500
+40% +$9.16M 4.55% 6
2017
Q1
$19.6M Hold
3,695,442
2.37% 14
2016
Q4
$26.5M Buy
3,695,442
+609,463
+20% +$4.93M 2.95% 7
2016
Q3
$28.9M Sell
3,085,979
-342,886
-10% -$2.85M 2.59% 11
2016
Q2
$21.7M Hold
3,428,865
2.11% 13
2016
Q1
$18.9M Hold
3,428,865
1.83% 14
2015
Q4
$19.1M Buy
3,428,865
+2,119,000
+162% +$14M 1.18% 18
2015
Q3
$11.1M Buy
1,309,865
+178,000
+16% +$3.01M 0.62% 41
2015
Q2
$17.1M Hold
1,131,865
0.92% 31
2015
Q1
$18.1M Sell
1,131,865
-127,606
-10% -$2.27M 1.41% 15
2014
Q4
$22.4M Sell
1,259,471
-182,964
-13% -$2.28M 1.95% 15
2014
Q3
$14.5M Buy
1,442,435
+625,000
+76% +$7.58M 1.52% 20
2014
Q2
$12.8M Buy
817,435
+150,000
+22% +$2.13M 1.24% 24
2014
Q1
$12.4M Buy
+667,435
New +$13.4M 1.2% 31

Other funds holding PETX

Broadfin Capital's PETX Position: Q3 2019 in Review

Broadfin Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 7,258,135 shares — an estimated $37.5M sold.

Broadfin Capital first reported a position in PETX in Q1 2014 and held it in 22 quarters. The position peaked at $37.5M in Q2 2017. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Broadfin Capital reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Broadfin Capital sold 7,258,135 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $37.5M.
  • Broadfin Capital first reported a position in Aratana Therapeutics, Inc. in Q1 2014 and held it in 22 quarters.
  • Broadfin Capital's Aratana Therapeutics, Inc. position peaked at $37.5M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Broadfin Capital's 13F filing for Q3 2019, filed 14 Nov 2019.